Truist Securities initiated coverage with a Buy rating on PTC Therapeutics, reviewing its pipeline for various genetic diseases.
1 report, 0 independent
Updated Jun 21
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Truist Securities initiated coverage with a Buy rating on PTC Therapeutics, reviewing its pipeline for various genetic diseases.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
PTC Therapeutics
pharmaceutical company
Nothing else this week.
Coverage
Newest first; wire copies grouped- Unknown outlet